The Microfluidic Immunoassay (MIA) market is expected to prosper driven by a growing demand for assay devices in hospitals…
Microfluidic immunoassays (MIA’s) are semiconductor-based devices where mechanisms or microsystems physically separate living cells or particles and detect the presence of specific biomolecules.
There is currently a great demand for MIA’s due to its unique characteristics such as consistent sensitivity, lower concentrations during the assay, easy automation, and environmental compatibility.
Click on the below tab to avail the Sample copy of the report
MIA Types and Applications
The Microfluidic Immunoassay (MIA) market is growing as it provides a cost-effective and rapid turnaround time for diagnostic testing. The MIA Market Analysis shows that the market for microfluidic immunomicro assay will grow at a CAGR of more than 20% over the next five years.
Leading Players in the MIA Market
The ESA Group is developing an MEIA Blood Test as a way to detect rapidly
growing tumors. This new technology is targeted at reducing the overall latency from tumor detection to
treatment.The commercially-oriented integration software market, which has reached $532million
by 2018, explains the need for this new technology.
Industry Supply Chain Analysis
The MIA market is forecast to reach $2.61 billion by 2020, at a compound annual growth rate (CAGR) of 23.01%. The global trend towards use of medical diagnostic systems employs stricter regulation on securely transferring biomaterials and requires faster turnaround times. This high-end equipment is leading to increased demand from hospitals and clinics in North America and Europe, which encompass a significant phase of the MIA market. Demand for the system remains strong in Asia, Latin America, and Middle East & Africa (MEA), especially due to high prevalence of risk factors in these regions such as diabetes mellitus or renal failure.
Click on the below tab for Instant Purchase of the report with flat $500 discount
The antibody market is witnessing in-depth technological advances. Era of nano-clotting (molecularase, colloidosomes) proteins and peptide synthetase, whose production’s cost has been lowered due to digital manufacturing have boosted the immunoassay industry’s performance. Furthermore, digital technology has improved the sensitivity while maintaining a high throughput. However, part of this advancement relies on detection technologies (such as sandwich ELISA and competitive protein technology). In addition, microfluidics are playing an increasingly important role across the industry.
Forecast to 2025
MIA market penetration forecasts for the period from 2015 to 2025 indicate a strong growth rate. One-time process costs such as sample preparation and cost of consumables are typically high, but with increasing demand in the healthcare infrastructure these investments will be more than offset by the increasing revenues. Press release
An elucidation of the market analysis over Microfluidic Immunoassay (MIA) is as follows: “”The MIA market is valued at $2,297.6 million thereabout and is predicted to be valued at $3,946.1 million by 2018.